A promoter of Ajanta Pharma Limited created a pledge on 245,000 shares and released a pledge on 115,000 shares. The creation of the pledge is for re-financing, while the release is for excess pledge. These transactions, executed around September 2025, affect the promoter’s encumbered holdings in the company. The updated shareholding details have been disclosed to both BSE and NSE.
Share Pledge Details
As of September 2025, a promoter of Ajanta Pharma Limited has engaged in pledge transactions involving the company’s shares. Specifically, a pledge has been created on a total of 245,000 shares. Simultaneously, a release of pledge occurred for 115,000 shares.
Reason for Pledge Activity
The official purpose stated for the creation of this pledge is for re-financing. The release of pledge is due to an excess pledge situation. This suggests adjustments being made to existing financial arrangements and collateral related to the promoter’s holdings.
Impact on Encumbered Holdings
Following these transactions, the promoter’s encumbered shareholding in Ajanta Pharma has been adjusted. Details regarding the pre and post-transaction percentages of encumbered shares are provided in the official disclosure made to the stock exchanges. As per the document, the post-release holdings of entities like Ravi P Agrawal Trust reflect the reduced encumbrance with a shareholding of 5,762,642 or 4.61%. The creation of pledge on 11-Sep-25 by the same entity resulted in 5,962,642 or 4.77% shareholding. Business financing served as a reason for pledge.
Entities Involved
The involved parties included Ravi Agrawal, trustee of Ravi Agrawal Trust, along with associated entities. The disclosure outlines the shareholding and encumbrance status across various promoter entities to provide a comprehensive view of the overall promoter group’s position in Ajanta Pharma.
Source: BSE
